Skip to content

Trial · Interventional

CompletedEarly phase 1Registry data

Oxytocin and Learning for Teaching

Overview

Status
Completed
Phase
Early phase 1
Enrollment
161 participants (actual)
Sponsor
University of California, Los Angeles · Other
Design
Randomized · Double masking
Countries
1 country

United States

Start
Jan 2015
Primary completion
Jul 2016
Completion
Jul 2016
First posted
19 Mar 2015 (estimated)
Last update posted
10 Aug 2017
Conditions
Social Psychology

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
201520162017
  1. Ph Early 1

    Oxytocin and Learning for Teaching

    NCT02393443

    Jan 2015 to Jul 2016

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

One well-established cognitive theory propose a divide between social and non-social (i.e., cognitive) systems. However, recent work suggests that traditionally social systems can be utilized to enhance cognitive performance. In this study the investigators aim to explore this cooperation between oft-competing systems by instructing participants to learn information because they will be subsequently tested (the nonsocial learning-for-testing condition), or because they will be teaching the information to someone else (the prosocial learning-for-teaching condition). This latter condition relies upon the mentalizing system, which is used to contemplate another person's mental state, rather than traditional memory systems. This implies that the mnemonic powers of the mentalizing system can be leveraged in the learning of a broad array of non-social topics. Furthermore, there is also an emerging literature on the role of oxytocin, a neuropeptide naturally produced in the hypothalamus, in memory that parallels the social/nonsocial split. Oxytocin may benefit the learning-for-teaching group both in terms of enhancing initial social motivation and efficient use of the mentalizing system and then also in terms of memory consolidation for this information learning under socially-motivated conditions. The investigators expect to replicate the basic learning-for-teaching effect such that those in the teaching condition will remember more than those in the testing conditions. They also expect an interaction between oxytocin administration and learning condition such that oxytocin administration should enhance learning for socially-motivated learning exclusively.

Interventions

  • Intranasal oxytocinDrug
  • Intranasal placeboDrug

Arms2

  • Experimental

    Intranasal oxytocin

    Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).

  • Placebo comparator

    Intranasal placebo

    2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Changes in brain neural activity, observed by fMRI, in response to a reading comprehension task

    Time frame · Between 40-90 minutes post administration

    Registry description

    Whole brain and region of interest (ROI) regression analysis will be used to compare the neural activity of participants in the tutor/memorizer and oxytocin/placebo groups. A design matrix will be created for each participant, modeling activity that is greater during reading comprehension compared with the grammar control passage. First level analyses will compare the response during the reading comprehension passages relative to the grammar control passages. Second level group analyses will compare the first level contrasts between the tutor vs. memorizer groups as well as the oxytocin vs. placebo groups. In regression analyses we will enter each participant's comprehension test score in the tutor and then memorizer condition as a regressor in a whole-brain and ROI analysis to determine which brain regions were more active during the encoding of the reading comprehension passage compared to the grammar control passage.

Secondary outcomes(1)
  1. Performance on a memory test of reading comprehension as measured by percentage of questions answered correctly

    Time frame · Between 40-90 minutes post administration

    Registry description

    Accuracy will be calculated for each participant by dividing the number of correct responses by the total number of questions. We will then conduct a between-subjects 2x2 ANOVA on the accuracy scores for the four groups of interest (i.e., oxytocin-tutor, oxytocin-memorizer, placebo-tutor, placebo-memorizer). A significance level of p\<.05 will be used to determine whether there are significant differences between the groups. We will examine whether there is a main effect of either factor (oxytocin vs. placebo, tutor vs. memorize) as well as an interaction between the factors of interest.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2023

5 results

Null results of oxytocin and vasopressin administration on mentalizing in a large fMRI sample: evidence from a randomized controlled trial.

Straccia et al. 2023Psychological medicinecited by 17

PMID 37310308PMC10123837DOI 10.1017/s0033291721004104PUB-37310308

CC BY5 results

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 30 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * 18-30 years of age * Healthy (see below) * Fluent in English * Right-handed Exclusion Criteria: * Women who gave birth in the last six months, are currently pregnant, planning to become pregnant in the next 6 months, or currently breastfeeding women * Symptoms of runny nose due to allergies/cold or other reason * Current restricted fluid intake for any reason * Heart disease * Hypertension * History of myocardial infarction * History of cardiac arrhythmia * Kidney or liver disease * Vascular disease * Epilepsy * Migraine * Asthma * Nephritis * Diabetes and other endocrine diseases * Frequent or unexplained fainting * History of stroke * Aneurysm or brain hemorrhage * Active psychiatric diagnosis * Current psychopharmacologic treatment * Drug or alcohol abuse * Medical or neurological illness * Regular use of medication (e.g., vasoconstrictive medications) * Medication intake less than 2 weeks prior to study (5 weeks for fluoxetine) including daily non-steroidal anti-inflammatory drugs * Smoking more than 15 cigarettes a day * Consumption of any alcoholic beverages in the past 24 hours will be excluded * Elevated blood pressure (\>135/90) * Low blood pressure (\<90/55) * Body temperature \>100.1 F * Left-handed * Claustrophobia * Presence of metal in their body

PepBank is a research reference. Talk to a doctor before you use any peptide.